Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Jiang, Wen G ^a   Ye, Lin ^a   Sanders, Andrew J ^a   Ruge, Fiona ^a   Kynaston, Howard G ^a   Ablin, Richard J ^b   Mason, Malcolm D ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cell matrix adhesion; Electric cell sensing; Focal adhesion kinase; Integrins; Paxillin; Prostate cancer; Transglutaminase; Transglutaminase 4

Indexed keywords

FOCAL ADHESION KINASE; PAXILLIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TGASE 4 GENE; TGASEP GENE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRINS; MALE; PAXILLIN; PROSTATE; PROSTATIC NEOPLASMS; TRANSGLUTAMINASES;

EID: 84886123916     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-269     Document Type: Article

References (30)

1. Dubbink HJ, de Waal L, van Haperen R, Verkaik NS, Trapman J, Romijn JC. The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization. Genomics 1998, 51:434-444. 10.1006/geno.1998.5393, 9721214.
2. Dubbink HJ, Hoedemaeker RF, van der Kwast TH, Schroder FH, Romijn JC. Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern. Lab Invest 1999, 79:141-150.
3. Grant FJ, Taylor DA, Sheppard PO, Mathewes SL, Lint W, Vanaja E, Bishop PD, O'Hara PJ. Molecular cloning and characterization of a novel transglutaminase cDNA from a human prostate cDNA library. Biochem Biophys Res Commun 1994, 203:1117-1123. 10.1006/bbrc.1994.2298, 7916568.
4. An G, Meka CS, Bright SP, Veltri RW. Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology 1999, 54:1105-1111. 10.1016/S0090-4295(99)00298-8, 10604718.
5. Cho SY, Choi K, Jeon JH, Kim CW, Shin DM, Lee JB, Lee SE, Kim CS, Park JS, Jeong EM, Jang GY, Song KY, Kim IG. Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer. Exp Mol Med 2010, 42:310-318. 10.3858/emm.2010.42.4.031, 2859330, 20177144.
6. Davies G, Ablin RJ, Mason MD, Jiang WG. Expression of the prostate transglutainase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Therapeut Oncol. 2007, 6:257-264.
7. Ablin RJ, Kynaston HG, Mason MD, Jiang WG. Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer. J Transl Med 2011, 9:49. 10.1186/1479-5876-9-49, 3113954, 21524313.
8. Jiang WG, Ablin RJ, Ye L, Kynaston HG, Mason MD. The prostate transglutaminase, TGase-4, coordinate with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells. Int J Oncol 2010, 37:413-418.
9. Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, Strongin AY. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001, 276:18415-18422. 10.1074/jbc.M010135200, 11278623.
10. Gerner C, Steinkellner W, Holzmann K, Gsur A, Grimm R, Ensinger C, Obrist P, Sauermann G. Elevated plasma levels of crosslinked fibrinogen gamma- chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb Haemost 2001, 85:494-501.
11. Mehta K. High-levels of transglutaminase expression in doxorubicin-resistant human breast-carcinoma cells. Int J Cancer 1994, 58:400-406. 10.1002/ijc.2910580316, 7914183.
12. Melino G, Annicchiarico-Petruzzelli M, Piredda L, Candi E, Gentile V, Davies PJ, Piacentini M. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994, 14:6584-6596. 359188, 7935379.
13. Fabbi M, Marimpietri D, Martini S, Brancolini C, Amoresano A, Scaloni A, Bargellesi A, Cosulich E. Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ 1999, 6:992-1001. 10.1038/sj.cdd.4400573, 10556977.
14. Zhang J, Guttmann RP, Johnson GV. Tissue transglutaminase is an in situ substrate of calpain: regulation of activity. J Neurochem 1998, 71:240-247.
15. Ruse M, Lambert A, Robinson N, Ryan D, Shon KJ, Eckert RL. S100A7, S100A10, and S100A11 are transglutaminase substrates. Biochemistry 2001, 40:3167-3173. 10.1021/bi0019747, 11258932.
16. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T, Aizawa S. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377:539-544. 10.1038/377539a0, 7566154.
17. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KSR, Cheresh DA, Schlaepfer DD. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003, 160:753-767. 10.1083/jcb.200212114, 2173366, 12615911.
18. Nazarenko IA, Bhatnagar SK, Hohman RJ. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res 1997, 25:2516-2521. 10.1093/nar/25.12.2516, 146748, 9171107.
19. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 1995, 55:5043-5048.
20. Giaever I, Keese CR. Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci USA 1991, 88:7896-7900. 10.1073/pnas.88.17.7896, 52411, 1881923.
21. Keese CR, Wegener J, Walker SR, Giaever I. Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci USA 2004, 101:1554-1559. 10.1073/pnas.0307588100, 341773, 14747654.
22. Jiang WG, Ablin RJ, Kynaston HG, Mason MD. The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvas Res 2009, 77:150-157.
23. Jeony LM, Murphy SNP, Radex JT, Lorand L. The fibronectin-binding domain of transglutaminase. J Biol Chem 1995, 270:5654-5658. 10.1074/jbc.270.10.5654, 7890687.
24. Cho SY, Jeon JH, Kim CW, Shin DM, Jang GY, Jeong EM, Lee SE, Song KY, Kim IG. Monoclonal antibodies to human transglutaminase 4. Hybridoma (Larchmt). 2010, 29:263-267. 10.1089/hyb.2009.0112, 20569004.
25. Gentile V, Grant FJ, Porta R, Baldini A. Localization of the human prostate transglutaminase (type IV) gene (transglutaminase-4) to chromosome 3p21.33-p22 by fluorescence in situ hybridization. Genomics 1995, 27:219-220. 10.1006/geno.1995.1032, 7665178.
26. Kim Y, Park YW, Lee YS, Jeoung DH. Yaluronic acid induces transglutaminase II to enhance cell motility; role of Rac1 and FAK in the induction of transglutaminase II. Biotechnol Lett 2008, 30(1):31-39.
27. McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, Hodivala-Dilke K, Metzger D, Chambon P, Grant SGN, Frame MC. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev 2004, 18:2998-3003. 10.1101/gad.316304, 535910, 15601818.
28. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 2012, Epub ahead of print.
29. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007, 67:10976-10983. 10.1158/0008-5472.CAN-07-2667, 18006843.
30. Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS, Cheng HC, Wang YC. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 2011, 71:473-483. 10.1158/0008-5472.CAN-10-1303, 21224350.